ArticleScientific reports2025
NKAIN1 expression relates to the immune evasion and prognosis of gastric cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Patients with gastric cancer often exhibit poor responses to immunotherapy and experience unfavorable outcomes. This study aims to investigate the relationship between NKAIN1 levels in the tumor microenvironment and gastric carcinoma patients characteristics. Gene expression analysis, multiplex immunohistochemistry using tissue microarrays, and Quantitative Pathology Imaging System were conducted for determining the expression of NKAIN1 in gastric carcinoma tissues and association with patient outcomes. Additionally, we used the Spearman correlation method to assess the relationship between NKAIN1 protein expression in the tumor immune microenvironment and immune checkpoint markers of gastric carcinoma. Lastly, we evaluated the predictive significance of NKAIN1 presence using Cox regression models. The study findings indicated a significant increase in NKAIN1 expression in gastric carcinoma tissues compared to non-tumor stomach tissues. Moreover, a clear association between NKAIN1 expression and CTLA-4, as well as PD-L1, was identified. Importantly, the increased NKAIN1 protein expression was identified as an independent prognostic factor for adverse clinical outcomes in gastric cancer. In conclusion, this study supports NKAIN1 as a prognostic marker and promising target for immune therapy in stomach carcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.